NASDAQ:ADAP
Adaptimmune Therapeutics plc Stock News
$1.08
+0.0150 (+1.42%)
At Close: Apr 26, 2024
JonesTrading Sticks to Its Buy Rating for Deciphera Pharmaceuticals (DCPH)
01:42pm, Tuesday, 28'th Apr 2020
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Deciphera Pharmaceuticals (DCPH). The company's shares closed last
JonesTrading Sticks to Its Buy Rating for Deciphera Pharmaceuticals (DCPH)
01:42pm, Tuesday, 28'th Apr 2020
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Deciphera Pharmaceuticals (DCPH – Research Report).
Adaptimmune Therapeutics PLC:
Mizuho Securities Sticks to Its Buy Rating for Merck & Company (MRK)
12:05pm, Tuesday, 28'th Apr 2020
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Merck & Company (MRK) today and set a price target of $100.00. The company's
Mizuho Securities Sticks to Its Buy Rating for Merck & Company (MRK)
12:05pm, Tuesday, 28'th Apr 2020
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Merck & Company (MRK – Research Report) today and set
Adaptimmune Therapeutics plc (ADAP), a leader in cell therapy to treat cancer, announced that the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positi
Why Did JonesTrading Downgrade Verastem's Stock?
07:49pm, Monday, 27'th Apr 2020
JonesTrading analyst Soumit Roy downgraded Verastem (VSTM) to Hold today. The company's shares closed last Monday at $2.12. According to TipRanks.com, Roy
Why Did JonesTrading Downgrade Verastem’s Stock?
07:49pm, Monday, 27'th Apr 2020
JonesTrading analyst
Soumit Roy
downgraded Verastem (
VSTM
–
Research Report
) to
Hold
today. The company’s shares closed last Monday at $2.12.
According to
TipRanks.com
, Roy is a 4-star analyst
Mizuho Securities Believes Iovance Biotherapeutics (IOVA) Still Has Room to Grow
09:46am, Monday, 27'th Apr 2020
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Iovance Biotherapeutics (IOVA) today and set a price target of $61.00. The company's
Mizuho Securities Believes Iovance Biotherapeutics (NASDAQ: IOVA) Still Has Room to Grow
09:46am, Monday, 27'th Apr 2020
Mizuho Securities analyst
Mara Goldstein
reiterated a
Buy
rating on Iovance Biotherapeutics (
IOVA
–
Research Report
) today and set a price target of
$61.00
. The company’s shares closed last Fri
Merck & Company (MRK) Receives a Buy from Mizuho Securities
02:55pm, Thursday, 23'rd Apr 2020
In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company (MRK), with a price target of $100.00.
Merck & Company (MRK) Receives a Buy from Mizuho Securities
02:55pm, Thursday, 23'rd Apr 2020
In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company (MRK –
The positioning of the Global T-Cell Immunotherapy Market vendors in FPNV Positioning Matrix are determined by Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel S
Adaptimmune Therapeutics (NASDAQ:ADAP) Earns Neutral Rating from Analysts at Mizuho
06:50am, Thursday, 23'rd Apr 2020
Equities research analysts at Mizuho began coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research note issued on Tuesday, MarketBeat reports. The brokerage set a “neutral” rati
BofA likes Johnson & Johnson in premarket analyst action
11:38am, Wednesday, 22'nd Apr 2020
Adaptimmune (NASDAQ:ADAP) initiated with Neutral rating and $3 (17% downside risk) price target at Mizuho Securities.Autolus Therapeutics (NASDAQ:AUTL) initiated with Buy rating and $18 (90% upside) p
